Although Lp2-CAR-T monotherapy was enough to moderately inhibit tumor growth, addition of the oncolytic virus G47Δ to CAR-T cell therapy drastically improved the antitumor efficacy. The gene discussed is RPLP2; the disease is neoplasm.